Skip to main content

Advertisement

SpringerLink
Log in

Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects

  • Original Research
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Purpose

A poor antibody response of IgM and IgA antibodies upon vaccination with pneumococcal polysaccharides (PnPS) is discussed as independent risk factors for bronchiectasis in patients with antibody deficiency syndrome (ADS) receiving immunoglobulin replacement therapy. However, the kinetics of the specific IgM and IgA response to vaccination with multivalent pneumococcal polysaccharides requires a more detailed knowledge. In this study we aimed i) to develop a standardised multivalent PnPS-IgM and IgA-ELISA, and ii) to compare the sensitivity of the multivalent to the serotype specific antibody response, and iii) to determine the kinetics of the anti-PnPS IgM and IgA antibodies in healthy subjects.

Methods

We immunised n = 20 healthy adults with a 23-valent PnPS vaccine (Pneumovax®). The kinetics of the 23-valent antibody response was assessed for 1 year with newly developed ELISAs for IgM and IgA isotypes, along with serotype specific responses.

Results

The IgA and IgM antibody response peaked at 2 and 3 weeks, respectively. IgM antibody levels remained at a plateau (above 80 % of peak response) for 3 months. After one year, specific antibody levels were still at about 30 % of the peak response. The 23-valent antibody response yielded significantly higher responder rates than assessment of single serotypes.

Conclusion

Testing the IgM and IgA immune response to polysaccharide vaccination with a multivalent PnPS ELISA may be a feasible tool for assessment of the immune function in patient groups who receive IgG replacement therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Grimwood K. Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr Respir Rev. 2011;12(2):111–8.

    Article  PubMed  Google Scholar 

  2. Tessmer A, Welte T, Schmidt-Ott R, Eberle S, Barten G, Suttorp N, et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J. 2011;38(1):147–53.

    Article  PubMed  CAS  Google Scholar 

  3. Tangye SG, Good KL. Human IgM + CD27+ B cells: memory B cells or “memory” B cells? J Immunol. 2007;179(1):13–9.

    PubMed  CAS  Google Scholar 

  4. Goldacker S, Draeger R, Warnatz K, Huzly D, Salzer U, Thiel J, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol. 2007;124(3):294–303.

    Article  PubMed  CAS  Google Scholar 

  5. Go ES, Ballas ZK. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol. 1996;98(1):205–15.

    Article  PubMed  CAS  Google Scholar 

  6. Sorensen RU, Leiva LE, Javier III FC, Sacerdote DM, Bradford N, Butler B, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. 1998;102(2):215–21.

    Article  PubMed  CAS  Google Scholar 

  7. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine. 2007;25(30):5467–84.

    Article  PubMed  CAS  Google Scholar 

  8. Carsetti R, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol. 2005;115(2):412–7.

    Article  PubMed  CAS  Google Scholar 

  9. Lortan JE, Kaniuk AS, Monteil MA. Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults. Clin Exp Immunol. 1993;91(1):54–7.

    Article  PubMed  CAS  Google Scholar 

  10. Musher DM, Watson DA, Baughn RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis. 1990;161(4):736–40.

    Article  PubMed  CAS  Google Scholar 

  11. Goldblatt D, Nahm M. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). 2010; Available at: http://www.vaccine.uab.edu/ELISAProtocol(89SF).pdf. Accessed 05/2012.

  12. van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J. 2005;25(3):482–9.

    Article  PubMed  Google Scholar 

  13. Murphy KM, Travers P, Walport M, Janeway CA, Seidler L, Ehrenstein M. Janeway Immunology. 6th ed.; 2007.

  14. O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7(9):597–606.

    Article  PubMed  Google Scholar 

  15. Alachkar H, Taubenheim N, Haeney MR, Durandy A, Arkwright PD. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol. 2006;120(3):310–8.

    Article  PubMed  CAS  Google Scholar 

  16. Cunningham-Rundles C. Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency. Clin Exp Immunol. 2009;157 Suppl 1:12–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2011) under grant agreement no201549 (EURO-PADnet)

Conflict of Interest

None of the authors has any potential financial conflict of interest related to this manuscript.

Author information

Authors and Affiliations

  1. Clinic for Immunodeficiencies, Paediatric Pulmonology, Allergy and Neonatology, Hanover Medical School, Carl-Neuberg Str. 1, 30625, Hanover, Germany

    Katharina Schütz & Ulrich Baumann

  2. The Binding Site Group Ltd., Birmingham, UK

    Richard G. Hughes & Antony Parker

  3. Clinical Immunology, Sapienza University of Rome, Rome, Italy

    Isabella Quinti & Monica Cavaliere

  4. Department of Clinical Immunology and Allergy, Medical Faculty of Masaryk University, St. Anne’s University Hospital, Brno, Czech Republic

    Vojtech Thon

  5. The Binding Site Deutschland GmbH, Schwetzingen, Germany

    Martina Würfel & Wilhelm Herzog

  6. Clinical Immunology and Rheumatology, Hanover Medical School, Hanover, Germany

    J. Engelbert Gessner

Authors
  1. Katharina Schütz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard G. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antony Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isabella Quinti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vojtech Thon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Monica Cavaliere
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martina Würfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wilhelm Herzog
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Engelbert Gessner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ulrich Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Baumann.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Fig. 1

Correlation between 23 PnPS antibody response pre and post vaccination. a.) Data for 23 PnPS IgM antibodies pre and 4 weeks post vaccination. b.) Data for PnPS IgA antibodies pre and 2 weeks post vaccination. The results are expressed as U/ml. Simple linear regression analysis is used (GIF 7 kb)

High resolution image (EPS 78 kb)

Supplementary Fig. 2

Correlation of PnPS-IgM response measured in 23 PnPS ELISA and in serotype specific assays. The left column show data before vaccination, the right column 2 weeks post vaccination. The results are expressed as μg/ml (GIF 13 kb)

High resolution image (EPS 128 kb)

Supplementary Fig. 3

Correlation of PnPS-IgA response measured in 23 PnPS ELISA and in serotype specific assays. The left column show data before vaccination, the right column 4 weeks post vaccination. The results are expressed as μg/ml (GIF 8 kb)

High resolution image (EPS 84 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schütz, K., Hughes, R.G., Parker, A. et al. Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects. J Clin Immunol 33, 288–296 (2013). https://doi.org/10.1007/s10875-012-9792-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-012-9792-y

Keywords

Search

Navigation